Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens.

Laura ArribillagaIciar EcheverriaViriginia BelsueTimothy GomezTeresa LozanoNoelia CasaresLorea VillanuevaSonia Domingos-PereiraPedro J RomeroDenise Nardelli-HaefligerSandra Hervás-StubbsPablo SarobeMaría Josefa RodriguezJosé L CarrascosaThomas ZürcherJuan Jose Lasarte

Published in: Journal for immunotherapy of cancer (2021)

Our results suggest that this therapeutic vaccine formulation may be an effective treatment for cervical tumors that do not respond to current therapies.

Keyphrases

high grade
endothelial cells
sars cov
drug delivery
dendritic cells
cervical cancer screening
pluripotent stem cells
combination therapy
type iii